Antibe Therapeutics: Difference between revisions
Content deleted Content added
Sternthinker (talk | contribs) brought status up-to-date, added key facts |
Sternthinker (talk | contribs) Updated references and added new key facts |
||
| Line 16: | Line 16: | ||
==Products== |
==Products== |
||
The [[mechanism of action]] of Antibe's drugs is the delivery of minute amounts of [[hydrogen sulfide]] to sites of inflammation within the human body.<ref> |
The [[mechanism of action]] of Antibe's drugs is the delivery of minute amounts of [[hydrogen sulfide]] to sites of inflammation within the human body.<ref>https://antibethera.com/science/why-h2s/</ref> Hydrogen sulfide has been shown to enhance the resolution of injury and repair of damage arising from tissue inflammation.<ref>{{cite journal | pmid = 26162834 | doi=10.1007/978-3-319-18144-8_8 | title=H2S and Inflammation: An Overview | date=2015 | journal= Handb Exp Pharmacol | pages=165-180}}</ref> Antibe's lead drug, ATB-346, is a hydrogen sulfide-releasing derivative of [[naproxen]], a commonly used [[non-steroidal anti-inflammatory drug]] (NSAID). ATB-346 is being developed to address [[osteoarthritis]], although Antibe intends to broaden its application to other types of chronic pain and diseases now treated with NSAIDs. Unlike standard naproxen, ATB-346 does not induce damage to the [[gastrointestinal tract]].<ref>British Journal of Pharmacology {{cite journal | pmid = 30834513 | doi=10.1111/bph.14641 | volume=177 | issue=4 | title=A proof-of-concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide-releasing anti-inflammatory drug. | date= February 2019 | journal= Br J Pharmacol | pages=769-777}}</ref> |
||
In May 2014, the company announced that it had completed [[pre-clinical development|pre-clinical studies]] on ATB-346.<ref>https://www.wsj.com/article/PR-CO-20140505-901386.html</ref> In late June 2014, following approval from [[Health Canada]], the company announced the first human dosing for Phase I of its [[clinical trial|human clinical trials]].<ref>http://www.marketwatch.com/story/antibe-therapeutics-announces-first-human-dose-of-atb-346-in-phase-i-clinical-trial-2014-06-26</ref> In mid-January 2015, the company announced that clinical trials for its |
In May 2014, the company announced that it had completed [[pre-clinical development|pre-clinical studies]] on ATB-346.<ref>https://www.wsj.com/article/PR-CO-20140505-901386.html</ref> In late June 2014, following approval from [[Health Canada]], the company announced the first human dosing for Phase I of its [[clinical trial|human clinical trials]].<ref>http://www.marketwatch.com/story/antibe-therapeutics-announces-first-human-dose-of-atb-346-in-phase-i-clinical-trial-2014-06-26</ref> In mid-January 2015, the company announced that clinical trials for its ATB-346 were being suspended due to safety concerns; clinical trials were restarted in March 2015.<ref>https://antibethera.com/news/antibe-therapeutics-provides-an-update-on-its-data-review-and-corporate-strategy/</ref> |
||
On March 20, 2018, Antibe Therapeutics announced successful results for Phase 2B gastrointestinal safety study for ATB-346.<ref>https://antibethera.com/news/antibe-therapeutics-announces-successful-phase-2b-gastrointestinal-safety-study-for-lead-pain-drug-atb-346/</ref> On June 1, 2020, Antibe announced positive results for ATB-346 (now known by its [[International Nonproprietary Name]], otenaproxesul) in its final Phase 2 trial, a dose ranging, efficacy study.<ref>https://antibethera.com/news/antibe-therapeutics-announces-positive-top-line-data-from-phase-2b-dose-ranging-efficacy-study-for-atb-346/</ref> The company's second drug, a opioid-replacement for post-surgical pain, is expected to start clinical trials in late 2021.<ref>https://antibethera.com/news/antibe-therapeutics-provides-corporate-update/</ref> |
|||
On March 20, 2018, Antibe Therapeutics announced successful results for Phase 2B Gastrointestinal Safety Study for its lead pain drug, ATB-346. On March 30, 2019, the company launched its final Phase 2B trial for ATB-346. |
|||
Antibe's products have not yet been approved by the US [[Food and Drug Administration]]. |
Antibe's products have not yet been approved by the US [[Food and Drug Administration]]. |
||
Revision as of 15:06, 13 August 2020
 Logo of Antibe Therapeutics | |
| Company type | Publicly traded corporation |
|---|---|
| TSX-V: ATE | |
| Industry | Pharmaceuticals |
| Founded | 1 January 2010  |
| Headquarters | Toronto , Canada |
Key people | Dan Legault JD, CEO; Alain Wilson, CFO; Dr. John L. Wallace, Chief Scientific Officer; Joseph Stauffer, Chief Medical Officer |
| Website | www |
Antibe Therapeutics is a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology.[1] Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.[2] On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug.[3]
Products
The mechanism of action of Antibe's drugs is the delivery of minute amounts of hydrogen sulfide to sites of inflammation within the human body.[4] Hydrogen sulfide has been shown to enhance the resolution of injury and repair of damage arising from tissue inflammation.[5] Antibe's lead drug, ATB-346, is a hydrogen sulfide-releasing derivative of naproxen, a commonly used non-steroidal anti-inflammatory drug (NSAID). ATB-346 is being developed to address osteoarthritis, although Antibe intends to broaden its application to other types of chronic pain and diseases now treated with NSAIDs. Unlike standard naproxen, ATB-346 does not induce damage to the gastrointestinal tract.[6]
In May 2014, the company announced that it had completed pre-clinical studies on ATB-346.[7] In late June 2014, following approval from Health Canada, the company announced the first human dosing for Phase I of its human clinical trials.[8] In mid-January 2015, the company announced that clinical trials for its ATB-346 were being suspended due to safety concerns; clinical trials were restarted in March 2015.[9]
On March 20, 2018, Antibe Therapeutics announced successful results for Phase 2B gastrointestinal safety study for ATB-346.[10] On June 1, 2020, Antibe announced positive results for ATB-346 (now known by its International Nonproprietary Name, otenaproxesul) in its final Phase 2 trial, a dose ranging, efficacy study.[11] The company's second drug, a opioid-replacement for post-surgical pain, is expected to start clinical trials in late 2021.[12]
Antibe's products have not yet been approved by the US Food and Drug Administration.
People
Antibe's science advisory board:[13]
- Andre G. Buret, Professor, University of Calgary, Canada
- Giuseppe Cirino, PhD, Professor, University of Naples, Italy
- Gilberto de Nucci, MD, PhD, Professor, University of Sao Paulo, Brazil
- Peter B. Ernst, DVM, PhD, Professor, UCSD, San Diego, USA
- Derek Gilroy, PhD, Professor, University College, London, UK
- Richard H. Hunt, MD, Emeritus Professor, McMaster University, Canada
- Louis Ignarro, PhD Professor, UCLA, Los Angeles, USA - 1998 Nobel Prize Laureate in Medicine
- Daniel K. Podolsky, MD, President, University of Texas Southwestern Medical Center, USA
- William Sessa, PhD, Professor, Yale University, USA
- Philip M. Sherman, MD, Professor, University of Toronto, Canada
Antibe's board of directors:[14]
- Chair - Walt Macnee, Vice Chair, MasterCard International[15]
- Roderick Flower, Professor Emeritus, Barts and The London School of Medicine and Dentistry
- Dan Legault, CEO, Antibe Therapeutics
- Amal Khouri, VP Business Development, Knight Therapeutics[16]
- John L. Wallace, Chief Scientific Officer, Antibe Therapeutics
References
- ^ http://www.antibethera.com
- ^ https://www.bloomberg.com/research/stocks/news/article.asp?docKey=600-201602021810BIZWIRE_USPRX____BW6697-1&ex=true&ticker=MNK
- ^ https://www.acsh.org/news/2020/08/05/antibes-non-opioid-pain-drug-otenaproxesul-looks-good-phase-iib-trials-14951
- ^ https://antibethera.com/science/why-h2s/
- ^ "H2S and Inflammation: An Overview". Handb Exp Pharmacol: 165–180. 2015. doi:10.1007/978-3-319-18144-8_8. PMID 26162834.
- ^ British Journal of Pharmacology "A proof-of-concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide-releasing anti-inflammatory drug". Br J Pharmacol. 177 (4): 769–777. February 2019. doi:10.1111/bph.14641. PMID 30834513.
- ^ https://www.wsj.com/article/PR-CO-20140505-901386.html
- ^ http://www.marketwatch.com/story/antibe-therapeutics-announces-first-human-dose-of-atb-346-in-phase-i-clinical-trial-2014-06-26
- ^ https://antibethera.com/news/antibe-therapeutics-provides-an-update-on-its-data-review-and-corporate-strategy/
- ^ https://antibethera.com/news/antibe-therapeutics-announces-successful-phase-2b-gastrointestinal-safety-study-for-lead-pain-drug-atb-346/
- ^ https://antibethera.com/news/antibe-therapeutics-announces-positive-top-line-data-from-phase-2b-dose-ranging-efficacy-study-for-atb-346/
- ^ https://antibethera.com/news/antibe-therapeutics-provides-corporate-update/
- ^ "Archived copy". Archived from the original on 2014-02-02. Retrieved 2014-02-12.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ http://antibethera.com/board-of-directors/
- ^ http://investorrelations.mastercardintl.com/phoenix.zhtml?c=148835&p=irol-govBio&ID=144740
- ^ https://www.gud-knight.com/category/management-team/